Compare Amgen, Inc. (AMGN) vs Rivian Automotive, Inc. (RIVN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Rivian Automotive, Inc. — how do they compare? Amgen, Inc. trades at $416.99 (market cap $224.14B), while Rivian Automotive, Inc. trades at $15.96 (market cap $23.69B). The key difference: Amgen, Inc. is far larger — about 9.5× Rivian Automotive, Inc.'s market cap, and Amgen, Inc. pays a 2.43% dividend while Rivian Automotive, Inc. pays none. Which is the better fit depends on your goals.
| AMGN | RIVN | |
|---|---|---|
Market Cap | $224.14B | $23.69B |
Sector | Health | Consumer Cyclical |
52-Week High | $417.20 | $22.45 |
52-Week Low | $271.18 | $11.97 |
Enterprise Value | $267.45B | $23.73B |
Dividend Yield | 2.43% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $417.44, up 0.06% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported strong Q2 2026 results, beating EPS estimates and raising full-year guidance, driven by robust product growth. Revenue reached $36.75B in 2025 with a net income margin of 22.95%, though high debt levels remain a focus.
Outlook is positive given earnings momentum and raised guidance, but risks include competitive pressures and a data breach investigation. Analyst consensus is Buy with a $394.69 price target, suggesting near-term consolidation after recent gains. The stock's valuation multiples are elevated relative to historical levels.
Rivian (RIVN) trades at $16.015, down 2.29% today, with a bullish technical signal from moving averages but neutral oscillators. The company shows improving fundamentals with revenue growth from $5.0B in 2024 to $5.4B in 2025, though net losses persist at -$3.65B. Recent R2 vehicle launches and raised 2026 delivery guidance to 65,000-70,000 vehicles indicate operational progress. Analyst consensus is mixed with 48% buy ratings and a $18.70 price target, suggesting 17% upside potential from current levels.
Rivian presents a high-risk growth opportunity with significant cash burn ($1.72B net outflow in 2025) but improving margin trends. The R2 ramp-up and Uber partnership offer catalysts, though execution risks and EV market competition remain concerns. With negative profitability metrics and substantial debt, the stock suits investors comfortable with early-stage company volatility seeking EV market exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Rivian Automotive, Inc.
Rivian Automotive, Inc. is an automotive technology company. The Company designs and manufactures vans, trucks, and sports utility vehicles, as well as offers repair and maintenance services. Rivian Automotive serves customers in North America and the United Kingdom.
Read more on RIVN →
